Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 202
- Registration Number
- NCT00860977
- Locations
- 🇨🇦
McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦University of Ottawa Health Services, Ottawa, Ontario, Canada
A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Epiphany Biosciences
- Target Recruit Count
- 373
- Registration Number
- NCT00831103
- Locations
- 🇺🇸
Center for Clinical Studies-Medical Center, Houston, Texas, United States
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 103
- Registration Number
- NCT00803543
- Locations
- 🇺🇸
Community Care Building, Birmingham, Alabama, United States
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00751270
- Locations
- 🇺🇸
The Ohio State University Medical Center, Dept Neurosurgery, Columbus, Ohio, United States
🇺🇸The Methodist Hosptial, Houston, Texas, United States
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
- Conditions
- Interventions
- First Posted Date
- 2008-05-22
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00682721
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- aRigen Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00652184
- Locations
- 🇺🇸
ARYS-0701 Site 12, Raleigh, North Carolina, United States
🇺🇸ARYS-0701 Site 3, Beverly Hills, California, United States
🇺🇸ARYS-0701 Site 4, New York, New York, United States
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
- Conditions
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00638612
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Scripps Green Hospital/Scripps Cancer Center, La Jolla, California, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00634231
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital), Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00589875
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸The Ohio State University Medical Center, Dept. Neurological Surgery, Columbus, Ohio, United States
Oral Valganciclovir Versus Valacyclovir
- Conditions
- Interventions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00562770
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.